Alzheimer's disease
| 4 min read
Trontinemab clears amyloid faster and more safely than previous drugs for Alzheimer’s disease. Will it convince skeptical regulators?
| 3 min read
Blood tests can’t diagnose Alzheimer’s disease yet, but one is already approved and more are on the way.
| 4 min read
Big-ticket licensing, FDA shake-ups, and Alzheimer’s data led the news this week.
| 2 min read
Enhanced Genomics’ 3D multi-omics platform harnessed to rapidly identify multiple novel therapeutic targets that were undetectable using conventional genomic approaches
| 10 min read
Learn about the latest advances in age-related macular degeneration (AMD) treatment, including a new drug that targets beta-amyloid to help prevent blindness and vision loss.
| 5 min read
Insights from the AD/PD meeting, continued fallout from the FDA layoffs, hope for GLP-1 drugs in Alzheimer’s disease, and more led industry news this week.
| 4 min read
A landmark UTI drug approval, new hope for the amyloid hypothesis in Alzheimer’s disease, a brewing vaccine study controversy, and more led the news this week.
| 4 min read
DDN editors break down a surprising connection between microplastics and antimicrobial resistance, vitamin D for multiple sclerosis, obesity drugs updates, and more news from this week.
| 8 min read
New gene therapies in clinical trials seek to treat Alzheimer’s disease and heal the brain with a dose of helpful genetic material.
| 3 min read
By watching brain organoids develop, researchers observed surprising abnormalities caused by mutations in a gene related to early-onset Alzheimer’s disease.
